More positive data validate Lilly's big bet on mirikizumab

17 March 2021
lilly-logo-big

Positive results from a trial of Eli Lilly’s (NYSE: LLY) monoclonal antibody mirikizumab raise the prospect of further competition in the gastrointestinal disorder space.

The anti-interleukin (IL_-23p19 antibody is being developed for moderate to severe ulcerative colitis (UC), and data now show the Phase III LUCENT-1 study met its goals in this indication.

Lilly’s competition is already racing ahead, with AbbVie’s (NYSE: ABBV) anti-IL-23 antibody Skyrizi (risankizumab‐rzaa) and Johnson & Johnson’s (NYSE: JNJ) Stelara (ustekinumab) making inroads in plaque psoriasis.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology